Skip to content
Saturday 29 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 27 January 2021 8:18 am  |  Updated:  Wednesday 27 January 2021 8:36 am

AstraZeneca CEO: ‘Britain will hit its vaccine targets’

By: Hannah Godfrey

Add as a preferred source on Google
Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
AstraZeneca's CEO Pascal Soriot has praised the UK's one-dose strategy, and believes the UK will hit its vaccine targets.

CEO of AstraZeneca Pascal Soriot is confident the UK will hit its vaccine rollout targets, and has confirmed AZ will not reconsider its pre-agreed contract with the UK in the face of supply shortages in the EU.

Speaking to Italian news site Repubblica, Soriot said the UK will have succeeded in vaccinating 28 to 30 million people, adding: “The Prime Minister has a goal to vaccinate 15 million people by mid-February, and they’re already at 6.5 million, so they will get there.”

The CEO also gave a thumbs up for the one-dose strategy being used by the UK at the moment in order to offer more people protection from the coronavirus over a shorter period of time.

“I think the UK one-dose strategy is absolutely the right way to go, at least for our vaccine,” he continued. “Oxford University conducted the so-called Oxford trial in the UK and Brazil, and we have data for patients who received the vaccine in one-month intervals, two and three months intervals.

“First of all, we believe that the efficiency of one dose is sufficient: 100 per cent protection against severe disease and hospitalisation, and 71-73 per cent of efficiency overall. The second dose is needed for long-term protection. But you get better efficiency if you do the second dose later than earlier.

“We are going to do a study in the US and globally to use two-month dose interval to confirm that this is indeed the case.”

AstraZeneca will slash the supply of its Covid vaccine to the EU by 60 per cent in the first quarter of 2020.

The company was expected to deliver to the 27 EU countries around 80 million doses by the end of March, but will now only be able to deliver 31 million doses.

Speaking to Repubblica, Soriot said his team were working 24/7 to fix the production issues at the company.

He said: “Our total capacity globally now is about 100 million doses a month. From February onwards we are able to make 100 million doses a month, so that’s not small. Most vaccines have 100 million doses a year. So that already takes us on a 1.2 billion pace per year.

“We are ramping up production and Europe is getting 17 percent of this global production in February for a population that is 5 percent of the world population.

“We are in the ramp up phase and basically it will improve, but it takes time. Having said all of this, I’m not looking for excuses, honestly.  We take accountability. We want to do better and we’re working day and night.”

Read more

Astrazeneca share price tumbles on $400bn megamerger talks

Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • Economists urge Bank of England to halt bond sales as borrowing costs climb

More from Morning Wire

  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

    Business Wire
  • Quaise Energy Closes $180 Million Series B with $35 Million Investment from Nabors Industries and Strategic Framework to Build World’s First Superhot Geothermal Power Plant

    Business Wire
  • Next hikes targets as heatwave boosts sales

    Retail
    Profit at Next rise 13.8 per cent in the first six months of the year
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook